{"id":"W2047725399","doi":"10.1016/j.clml.2013.03.020","title":"Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Teva Pharmaceutical Industries","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Clinical endpoint; Confidence interval; Myeloid leukemia; Surgery; Randomized controlled trial; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001209564,0.0002227377,0.0003666009,0.0001599536,0.0001965464,0.0001714544,0.0001246319,0.0002446388,0.001181705],"category_scores_gemma":[0.0003424473,0.0000857513,0.000266961,0.0002617188,0.0001815825,0.0002338712,0.0001393476,0.000360838,0.0001225109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002591083,"about_ca_system_score_gemma":0.0004382503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00119193,"about_ca_topic_score_gemma":0.004145372,"domain_scores_codex":[0.9999428,0.00001454552,0.00000552349,0.000007138254,0.000009382557,0.00002061124],"domain_scores_gemma":[0.9998994,0.00002077392,0.00002388975,0.000002963335,0.000003230532,0.00004985505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1278069,0.003721345,0.4953143,0.0006483312,0.000915784,0.01875053,0.0004842467,0.00272094,0.075642,0.0006959612,0.006692551,0.2666071],"study_design_scores_gemma":[0.01565917,0.06160232,0.8775311,0.0001440037,0.0007462982,0.019617,0.0005731338,0.003199181,0.007522154,0.0006239701,0.01273628,0.00004548864],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948123,0.002248489,0.00008373731,0.0004541327,0.00004652822,0.00003617593,0.0001077364,0.00001154534,0.002199437],"genre_scores_gemma":[0.9986791,0.0007326925,0.00006901036,0.0001325255,0.00003126383,0.00001097627,0.00009741518,0.000001085446,0.0002458014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00119193,"threshold_uncertainty_score":0.003953159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01974581216089715,"score_gpt":0.3045457770249775,"score_spread":0.2847999648640803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}